Estrogen therapy is a medical treatment that supplements the body’s estrogen levels, most commonly used to relieve menopause symptoms like hot flashes, night sweats, and vaginal dryness. It is the most effective treatment available for these symptoms and also helps prevent bone loss after menopause. While estrogen therapy has clear benefits for many women, the timing of when you start, the form you use, and your personal health history all shape whether it’s the right choice.
Why Estrogen Levels Drop
Estrogen is a hormone that influences dozens of processes throughout the body, from bone maintenance to temperature regulation to the health of vaginal and urinary tract tissue. During menopause, the ovaries stop producing significant amounts of estrogen, and levels drop sharply. This decline triggers the symptoms most women associate with menopause: hot flashes, night sweats, sleep disruption, vaginal dryness, and discomfort during sex. It also accelerates bone loss, raising the long-term risk of osteoporosis and fractures.
Estrogen therapy works by restoring some of that lost estrogen. When supplemental estrogen enters the body, it binds to estrogen receptors found in cells throughout your tissues, including bone, brain, blood vessels, and reproductive organs. That binding reactivates many of the protective and regulatory functions that slowed or stopped when natural production declined.
What Estrogen Therapy Treats
The FDA has approved estrogen therapy for three primary uses: moderate to severe hot flashes and night sweats (known as vasomotor symptoms), vaginal dryness and discomfort caused by lower estrogen levels, and prevention of postmenopausal bone loss.
For hot flashes, the results are substantial. At a standard dose, estrogen therapy reduces moderate to severe hot flash episodes by roughly 75% to 80% after about 12 weeks. Even low-dose estrogen cuts episodes by around 65%, which is significantly better than the 35% to 40% improvement seen with placebo. For someone experiencing 80 or more episodes per week, that difference translates to going from constant disruption to a handful of manageable moments.
For bone health, estrogen slows the accelerated bone breakdown that follows menopause and allows new bone formation to catch up. Data from the Women’s Health Initiative, the largest randomized trial of hormone therapy, showed a 24% to 39% reduction in osteoporotic fractures. That benefit held even in women who weren’t considered high risk for fractures, making estrogen one of the few treatments shown to protect bones across a broad population.
Systemic vs. Local Estrogen
Estrogen therapy comes in two broad categories: systemic and local. Systemic therapy circulates estrogen throughout your entire body and treats hot flashes, night sweats, and bone loss. It’s available as pills, skin patches, gels, creams, and sprays. Local therapy delivers estrogen directly to vaginal tissue at much lower doses and is designed specifically for vaginal dryness, painful intercourse, and urinary symptoms. Local forms include vaginal creams, tablets, and rings.
Transdermal options (patches, gels, sprays) have become increasingly popular since the early 2000s because estrogen absorbed through the skin bypasses the liver, which may lower the risk of blood clots compared to oral pills. However, different formulations can vary in how much estrogen your body actually absorbs, so your doctor may need to adjust your dose based on how well your symptoms respond.
If your only bothersome symptoms involve vaginal or urinary discomfort, low-dose vaginal estrogen is generally preferred over systemic therapy. It effectively relieves dryness and irritation and also reduces the risk of recurrent urinary tract infections, all with minimal absorption into the rest of your body.
The Progestogen Question
If you still have your uterus, taking estrogen alone significantly raises the risk of endometrial hyperplasia, a thickening of the uterine lining that can progress to uterine cancer. Adding a progestogen (a synthetic form of progesterone) to your estrogen therapy dramatically reduces that risk. This combination is standard practice for anyone with an intact uterus using systemic estrogen.
Women who have had a hysterectomy can typically take estrogen alone, since there’s no uterine lining to protect. Low-dose vaginal estrogen, because so little enters the bloodstream, generally does not require a progestogen addition, though your doctor will factor in your specific situation.
When You Start Matters
One of the most important findings in estrogen therapy research is that timing changes the risk profile considerably. This concept, called the “timing hypothesis,” emerged after researchers noticed a striking pattern: the Women’s Health Initiative trial, which raised widespread concern about hormone therapy in 2002, enrolled women who were an average of 63 years old and about 12 years past menopause. That’s much later than most women would typically start therapy in real life.
When researchers broke the data down by age and time since menopause, the picture shifted. Women who started estrogen within 10 years of menopause onset, or before age 60, showed trends toward cardiovascular benefit rather than harm. In the Nurses’ Health Study, women who began therapy near menopause had a 34% lower risk of coronary heart disease with estrogen alone and a 28% lower risk with estrogen plus progestogen. Women who waited more than 10 years saw no such benefit.
The likely explanation is that estrogen helps keep healthy blood vessels flexible and resistant to plaque buildup, but once significant atherosclerosis has already developed, adding estrogen can destabilize existing plaques. Animal studies reinforce this: estrogen started immediately after ovary removal reduced coronary artery disease by 50% to 70%, while the same treatment delayed by the equivalent of six human years had no benefit at all.
Current guidelines from the North American Menopause Society reflect this evidence. For women younger than 60 or within 10 years of menopause with no contraindications, the benefit-risk ratio favors treatment. For women who are older than 60 or more than 10 years past menopause, the balance tips toward greater risk of heart disease, stroke, blood clots, and dementia.
Who Should Not Use Estrogen Therapy
Certain health conditions make estrogen therapy too risky. These include:
- History of breast cancer
- History of blood clots (deep vein thrombosis or pulmonary embolism)
- History of stroke
- Coronary artery disease
- Uncontrolled high blood pressure
- Migraine with aura
- Current smoking over age 35 (for combined hormonal products)
Some of these are absolute contraindications, while others depend on severity and your overall risk profile. Women with migraines without aura who are under 35, for example, may still be candidates depending on the formulation.
Common Side Effects
The most frequently reported side effects of estrogen therapy are breast tenderness, nausea, bloating, headaches, and mood changes. Some women on combined estrogen-progestogen therapy also experience vaginal bleeding, particularly in the first few months. These side effects are often manageable. Switching from a pill to a patch, adjusting the dose, or trying a different progestogen regimen can resolve most issues without stopping treatment entirely.
Side effects tend to be most noticeable in the first weeks to months of therapy and often improve as your body adjusts. If they persist or worsen, that’s usually a signal to revisit the dose or delivery method rather than to abandon therapy altogether.
How Long Treatment Typically Lasts
There’s no single right answer for how long to stay on estrogen therapy. Current guidance recommends using the lowest effective dose for the shortest duration needed, with periodic check-ins to reassess whether continuing makes sense. For many women, vasomotor symptoms last several years and then taper off, making a few years of treatment sufficient. Others experience symptoms well into their 60s or beyond and may benefit from longer use.
Longer durations of therapy are considered appropriate when there’s a documented, ongoing need, such as persistent hot flashes or continued bone loss risk. The decision to continue is best made collaboratively, weighing your current symptoms, risk factors, and how you respond to treatment over time. The risks of therapy, particularly blood clots and stroke, do increase modestly with duration, so staying on estrogen indefinitely without reassessment is not recommended.